Company Info

Management Team

Co-founder, first CEO and chairman (1999-2010) of the board of Tranzyme Pharma, Inc. (NASDAQ:TZYM).
Former General Partner of Pacific Rim Ventures, a Tokyo-based VC firm
Former CEO of Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), a company specializing in respiratory tract and mucous membrane therapeutics that was sold subsequently to Merck & Co. Inc. (NYSE:MRK).
Former Director of MethylGene Inc. (TSX:MYG), a clinical-stage biopharmaceutical company, engaged in the discovery and development of therapeutics for cancer and infectious diseases.
Former Vice President Biological Sciences and Vice President Clinical Research at Smith Kline and French Laboratories.
Former Vice President Clinical Development at Daiichi Pharmaceutical Corporation (cancer and infectious diseases).
Previous senior faculty positions at UC San Francisco, University of Texas Health Science Center, San Antonio and the University of Pennsylvania.
Former US Navy medical officer.
Received Medical Degree - University of Louisville; postgraduate training - Vanderbilt University
Fellow, American College of Physicians and Infectious Diseases Society of America.
Current Board affiliations: Gentris Corporation; Vaxin, Inc. (Chairman); Genome Canada (SIAC: Science and Industry Advisory Committee).

Co-founder of Oncogenerix, Inc. a privately-held specialty biopharmaceutical company focused on the in-licensing of oral liquid formulations and oncology-support therapeutics, which was acquired by DARA.
Former President and CEO of Savient Pharmaceuticals Inc. (NASDAQ:SVNT); refocused company to specialty pharmaceutical company which resulted in a $1 billion market valuation.
Former Chairman and CEO of Epicyte PharmaServed as Executive VP, Senior VP and Chief Marketing Officer at Ares-Serono GroupHeld a number of senior management positions at Searle Pharmaceuticals LLC - Current Board affiliation: Neos Therapeutics.
BA in Marketing and Business – Mercy College.

Former Principal of Stratium Consulting Services, specializing in strategic and financial planning and management, corporate governance and business development.
Former Secretary, Treasurer and CFO of PediatRx, Inc. (OBB: PEDX).
Former Executive VP and CFO at airPharma, LLC, where he successfully led and completed divestiture of a product line to a UK company.
Held senior management positions at PediaMed Pharmaceuticals., Inc.; AVAX Technologies, Inc. (OTC: AVXT); Pasteur Merieux Connaught (now Sanofi Pasteur).
MBA from Rutgers Graduate School of Management.
Certified Public Accountant in the state of New Jersey.

Co-founder of Oncogenerix
Served as VP of Strategic Partnerships & VP of Sales and Marketing of Savient Pharmaceuticals (NASDAQ:SVNT); instrumental in the successful launch and commercial development of Oxandrin.
Held management position at Genentech, Inc., led sales efforts for all commercial products in the New England Region.
Former National Sales Director of Insmed Incorporated (Nasdaq:INSM)President of DBI Consulting: worked on the product launches of Mozibil (Genzyme), Kuvan )(BioMarin), and Zanaflex (Accorda).
BS Degree in Business Administration – Northeastern University.

Co-founder of Oncogenerix.
20 year career with pharmaceutical and small biotechnology start-up companies, including Theravance, Inc. (NASDAQ: THRX); Syntex/Roche, operating subsidiary of Roche Holding (SWX:ROG); and Boehringer-Ingelheim GmbH.
Participated in the development of products from early development through FDA approval, including OSSIGEL (bFGF injection), Ganirelix, VIBATIV (telavancin injection), and other proprietary anti-infective and oncology products.
PhD in Chemical Engineering – Johns Hopkins University